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Abstract
Background: The prevalence of cardiovascular disease has been increasing worldwide. As a common pathogenic
risk factor, dyslipidemia played a great role in the incidence and progress of these diseases. We investigated to
achieve accurate and up-to-date information on the prevalence of dyslipidemia and its associations with other
lipid-related diseases in rural North China.
Methods: Using a complex, multistage, probability sampling design, we conducted a large-scale cross-sectional
study of 8528 rural participants aged over 18 years in Shandong Province. Prevalence and characteristics of
dyslipidemia were demonstrated. The odds ratios between dyslipidemia types and lipid-related diseases were
further analyzed by logistic regression.
Results: Among the overall population, 45.8 % suffered from dyslipidemia. The prevalence of lipid abnormality
(including high and very high levels) was 18.6, 12.7, 9.8 and 12.7 % for total cholesterol (TC), high-density
lipoprotein (HDL), and low-density lipoprotein (LDL) cholesterol and triglycerides (TG), respectively. Among
all participants with dyslipidemia, 23.9 % were aware, only 11.5 % were treated, 10.0 % were controlled. For subjects
with dyslipidemia, the risk for non-alcoholic fatty liver disease (NAFLD) was highest with a 3.3-fold over that of
non-dyslipidmia (OR = 3.30, P < 0.001); followed by hyperuricemia and diabetes mellitus (DM), while with 2-fold
increase (OR = 1.99, P < 0.001; OR = 1.92, P < 0.001); with only 1.5-fold risk for atherosclerosis (AS) (OR = 1.47, P < 0.001).
The presence of high cholesterol was mainly associated with AS, while abnormal TG was correlated with NAFLD
and DM.
Conclusions: Dyslipidemia has become a serious public health issue in rural North China. The rapid increase of high TC
and incremental risk of high TG may contribute to the epidemic of AS, NAFLD and DM. It is imperative to develop
individualized prevention and treatment guidelines according to dyslipidemia phenotypes.
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Background
Dyslipidemia is the established modifiable risk factor for
cardiovascular diseases, which account for a ubiquitous
cause of morbidity and a leading contributor to mortality
in most developing countries [1]. As a common pathogenic
risk factor, it has been accepted that dyslipidemia accounts
for the rising of diabetes mellitus (DM), atherosclerosis
(AS) and non-alcoholic fatty liver disease (NAFLD) [2, 3],
which all lead to the health burden worldwide.
Over the past decades, with the development of
economics and changes in lifestyles, dyslipidemia has
been projected to increase in absolute number in
China [4–6]. Estimated by a nationally representative
sample of 46,239 adults aged 20 years among Chinese
population, 31.5 % or 308 million persons had border-
line high or high total cholesterol, whereas 20.4 % or
196 million persons have a borderline high, high, or
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very high level of LDL cholesterol [6]. This study mainly
paid attention on cholesterol and lacked a detailed de-
scription on triglycerides; in addition it had not provided
the prevalence and characteristics of rural dyslipidemia.
However, based on China’s national conditions, more than
half (50.3 %) of the Chinese population are spread in rural
areas [7]. Compared with the population in urban areas,
people in rural areas relatively have low income, limited
medical costs reimbursement and inequitable allocation of
healthcare resources [8], all which pushed less health edu-
cation, even lack of detailed reports for lipid profiles in
contrast with urban areas.
Therefore, knowledge of the current magnitude of
dyslipidemia in rural population is important for per-
fect health care resource allocation and prevention and
management of CVD-related diseases, in turn to attenuate
the society medical burden. However, in recent years, there
are relatively few and timely epidemiologic descriptions
that elaborating the lipid profiles and their relationships
with lipid-related diseases in rural population in North
China. The current study aimed (a) to depict the preva-
lence of dyslipidemia among rural population in 2014; (b)
to estimate the awareness, treatment and control rate of
dyslipidemia; (c) to determine the associations between
dyslipidemia phenotypes and lipid-related diseases, in
order to achieve better control of DM, AS, NAFLD and
hyperuricemia among rural population.
Methods
Study design and groups
Participants in the cross-sectional study were obtained
from rural areas of Shandong Province, using a multiple-
stage stratified sampling method in 2014. A total of 12
towns were involved. Sample size in every town or village
was based on geographic region, population size, and eco-
nomic status [9]. All residents aged over 18 years who had
been living in their current village for 5 years or longer
were invited to attend the study by telephone or door-to-
door visits. The participants were excluded if they were
pregnant or with incomplete vital data such as age,
gender, lipid profiles, serum uric acids level, blood glu-
cose and ultrasonic examination. Finally, 8528 subjects
were selected.
The study protocol was approved by the ethics
committee of Shandong Provincial Hospital affiliated
to Shandong University, and all participants provided
written informed consent before collecting data.
Data collection
The survey consists of health information interview,
physical examination, and extensive laboratory testing.
Data collection was conducted at local health stations in
the participants’ residential area by well-trained medical
staff. The interview included questions related to the
information on demographic and social characteristics,
the diagnosis and treatment of dyslipidemia and other
cardiovascular events. Current smokers were defined as
those who had smoked ≥100 cigarettes in their lifetime
and currently smoking cigarettes at the time of the
survey. Current drinking was defined as alcohol intake
more than once per month during the past 12 months.
Blood pressure and anthropometric measurements were
measured according to standard protocols [10]. Blood
pressure was presented by the means of three measure-
ments with the participant in a sitting position after
5 min of rest using an electronic sphygmomanometer
(HEM-7117; Omron, Kyoto, Japan).
Blood samples were collected from participants after
an overnight fast of at least 10 h. An oral glucose toler-
ance test (OGTT) was given to each participant without
a self-reported history of diabetes. Serum and plasma
samples were shipped in dry ice. The serum lipid pro-
files and hepatic and renal functions were measured
using an automatic biochemistry analyzer (Olympus
AU5400, Tokyo, Japan) in the clinical laboratory affili-
ated with Shandong University. The intra-assay and
interassay coefficients of variation were always below
5 % for all of the above parameters.
All participants were performed abdominal and carotid
intima-media thickness (CIMT) examination. The presence
of fatty liver and AS was detected by color ultrasonic diag-
nostic apparatus equipped with a 9 MHz linear-array
transducer (Toshiba Aplio 500 Ultrasound Scanner). The
subjects were in the supine position, with the head
tilted backwards. Two different longitudinal-view ob-
servations of the bilateral carotid artery were made at
the common carotid artery (10 mm before the bulb)
and the carotid bulb (10 mm cranially to the start of
the bulb), both including the left anterior wall, the left
posterior wall, the right anterior wall and the right pos-
terior wall. The radiologists sought the segments of
greatest thickness and the plaque lesions along the
arterial walls. The carotid artery intima-media thickness
is defined as the viewable distance between the intima-
lumen and the media-adventitia interface of the artery.
Three values of IMT were conducted at the site of the
thickest point and two adjacent points. The three
measurements were averaged as the mean-IMT. The
greatest value among the eight mean-IMTs was the
max-IMT [11].
Diagnostic criteria and definitions
Dyslipidemia was defined as total cholesterol (TC)
≥6.22 mmol/L (≥240 mg/dL), and/or triglycerides
(TG) ≥1.70 mmol/L (≥150 mg/dL), and/or LDL
cholesterol ≥4.14 mmol/L (≥160 mg/dL), and/or HDL
cholesterol <1.04 mmol/L (<40 mg/dL), and/or use of
lipid-lowering medications [12]. The phenotypes of
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dyslipidemia were defined as follows: isolated hypercholes-
terolemia (Type 1), isolated hyperglyceridemia (Type 2),
low HDL level alone (Type 3) and mixed dyslipidemia,
which was further defined as (a) the presence of high TC/
LDL-C and high TG (Type 4); (b) both elevated TG levels
and low HDL-C (Type 5) [13, 14]. A person with dyslipid-
emia according to the ATP III definition was considered
“aware” if the participant gave a positive response to the
question, “Have you ever been told by a doctor or other
health professional that your blood lipid profiles level was
high?” Those who reported taking lipid-lowering drugs
were considered “treated”. Dyslipidemia was considered to
be controlled among the population defined as having
dyslipidemia if TC <6.22 mmol/L, LDL-C <4.14 mmol/L,
HDL-C ≥1.04 mmol/L, and TG<1.70 mmol/L. Diabetes
was defined in accordance with the American Diabetes
Association 2010 criteria:(1) a self-reported previous diag-
nosis by health care professionals, (2) fasting plasma glu-
cose level of 126 mg/dl (7.0 mmol/L) or higher, (3) 2-h
plasma glucose level of 200 mg/dl (11.1 mmol/L) or
higher, or (4) HbA1c concentration of 6.5 % or more [15].
Hyperuricemia was defined by patients with the higher
level than 7 mg/dl for men, and 6 mg/dl for women
[16]. Hypertension was defined as a systolic blood pres-
sure of 140 mmHg or higher, a diastolic blood pressure
of 90 mmHg or higher, or being told by a doctor or
health care professional on two or more different visits
that he/she had hypertension [17]. Overweight was de-
fined as a BMI of 24.0 to 27.9, and obesity was defined as
a BMI of 28.0 or higher [18]. According to current sono-
graphic criteria: we refer to the maximum IMT (max-
IMT) <0.9 mm was “normal”; the max-IMT >0.9 mm was
considered indicative of thickened intima, while max-
IMT >1.3 mm indicative of atherosclerotic plaque [11].
Fatty liver was diagnosed when a patient met any two of
the three following ultrasonic criteria: liver and kidney
echo discrepancy and presence of increased liver echo-
genicity (bright); unclear intrahepatic duct structure;
liver far field echo decay [19]. NAFLD was excluding pa-
tients with potential cause of chronic liver disease, such as
excessive alcohol consumption, hepatitis, or taking medi-
cations with a known association with fatty liver [19].
Statistical analysis
Demographic and biochemical indexes were described in
the overall population, using percentages for categorical
variables and means for continuous variables. Mean
levels of total, HDL, and LDL cholesterol and triglycer-
ides were estimated for the overall population by sub-
groups. Differences between mean values were tested
using Student’s t-test, and differences between propor-
tions were tested using the chi-square test. Serum total,
HDL, and LDL cholesterol levels were classified on the
basis of the Third Report of the Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in
Adults [12],see supplement Additional file 1: Table S1 for
specific content. The prevalence estimates of total, HDL,
and LDL cholesterol categories were calculated for the
overall population and by gender and age groups, and
linear trends for age-specific prevalence were tested
using the linear-by-linear association chi-square test.
Next, we compared the awareness, treatment and control
of dyslipidemia between different gender and age groups.
Logistic regression models were used to analyze the
adjusted odds ratios (ORs) and 95 % confidence interval
(CI) of dyslipidemia clinical types for the development of
DM, NAFLD, AS and hyperuricemia, while controlling
for potential confounders. The covariates in the multi-
variable model 2 selected for clinical importanc and for
statistical significance included the age, sex, body mass
index, smoking status, drinking status, liver function,
hypertension, hyperuricemia, diabetes mellitus, NAFLD
and atherosclerosis.
Furthermore, we analyzed the coefficient of lipid pa-
rameters for the increase of CIMT, FPG, ALT/AST and
uric acids per 1-SD increase in lipid parameters. To
facilitate comparisons, the levels of lipid parameters
were scaled to a mean of 0 and a standard deviation
(SD) of 1. Two sided p value less than 0.05 was considered
to be significant. Statistical analyses were conducted using
SPSS 18.0 for Windows (SPSS, Chicago, IL, USA).
Results
Basic characteristics of the overall participants
A total of 8528 (3402 men and 5126 women) partici-
pants were included in our study. The overall prevalence
of dyslipidemia was 45.8 %. Social behavior characteristics
and serum levels of related indexes among the participants
were summarized in Table 1. Significant differences of the
variables were observed, except for drinking status. Sub-
jects with dyslipidemia were inclined to be men and had
older age, higher blood pressure, BMI and waist circum-
ference, and were more likely to have a habit of smoking
currently or in the past. In addition, the levels of liver
function (AST, ALT and GGT), plasma glucose, HbA1c,
uric acid and eGFR were all higher in dyslipidemia
patients.
Prevalence of dyslipidemia among the overall population
according to age and gender
The mean levels of lipid profiles among the overall
population (N = 8028) were shown in Additional file 1:
Table S2 by age, gender, BMI and fasting plasma glucose
(FPG) groups.
Table 2 and Fig. 1 depicted the proportions of adults
with lipid fractions by gender and age. Lipid profiles
were categorized according to ATP III classifications. As
is shown in Table 2, half (53 %) of all participants had
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abnormal levels of total cholesterol, and among them,
high TC (≥6.22 mmol/L) accounted for one-third. While
only 32.8 % of the overall population had increased
LDL-cholesterol levels, mainly with borderline high level
(3.37–4.13 mmol/L). Additionally, nearly one fourth suf-
fered from TG abnormality, and among these, borderline
high (1.70–2.25 mmol/L) and high (2.26–5.63 mmol/L)
concentrations had the most cases; very high TG
(≥5.64 mmol/L) was less than 2 %. Prevalence of low
HDL cholesterol was 12.7 % for the overall population.
Men were inclined to suffer higher prevalence of lipid
abnormities than women (Table 2).
Trends in age-specific prevalence of lipid abnormities
were presented in Fig. 1. With aging, proportions for ab-
normal TC and LDL-C increased linearly (P < 0.001),
and reached a peak in 60–69 group, then stayed flat or
declined slightly (Fig. 1a, b). Borderline high TG concen-
trations (1.70–2.25 mmol/L) were basically linear in-
crease, summit in 70 years and older (P < 0.001, Fig. 1d).
However, prevalence of very high TG level declined with
advanced age (P = 0.004, Fig. 1d). Lower levels of HDL-C
may increase the cardiovascular risk. As the figure shown,
proportions of this low HDL (<1.04 mmol/L) concen-
trations decreased with increased age group (P < 0.001,
Fig. 1c).
Awareness, treatment and control of dyslipidemia
Subsequently, Fig. 2 depicted the age- and gender-specific
awareness, treatment and control of dyslipidemia. Among
all participants with dyslipidemia, 23.9 % (22.6 %, 25.3 %)
were aware, only 11.5 % (10.5 %, 12.5 %) were treated,
10.0 % (9.0 %, 10.9 %) were controlled. Compared with
men, women were more likely to be aware and treated,
though not statistically significant. Moreover, women have
a significantly higher control rate (P = 0.02, Fig. 2a). The
proportion of awareness, treatment for dyslipidemia sig-
nificantly increased with age until peaks for 60–69 age
group (Fig. 2b, c). Despite of increase over age ranges as
well, the control rates hit the peak in 70 years and older
(Fig. 2d).
Table 1 The basic characteristics of the study participants according to dyslipidemia statusa
Variables Dyslipidemia Non-dyslipidemia P-value
(N = 3905) (N = 4623)
Male, % 51.4 (49.7, 53.1) 48.6 (46.9, 50.3) <0.001
Age, ys 53.25 (52.87, 53.64) 51.05 (50.66, 51.43) <0.001
SBP, mmHg 137.68 (137.05, 138.32) 132.08 (131.49, 132.67) <0.001
DBP, mmHg 80.88 (80.5, 81.25) 77.61 (77.27, 77.95) <0.001
BMI, kg/m2 26.54 (26.41, 26.67) 24.81 (24.7, 24.93) <0.001
Waist circumferencce, cm 91.3 (90.92, 91.67) 86.04 (85.69, 86.4) <0.001
ALT, U/L 22.25 (21.6, 22.89) 17.75 (17.39, 18.12) <0.001
AST, U/L 24.3 (23.62, 24.98) 22.8 (22.51, 23.09) <0.001
GGT,U/L 37.71 (36.46, 38.95) 24.53 (23.7, 25.37) <0.001
Creatinine 68.97 (68.51, 69.44) 64.87 (64.47, 65.26) <0.001
Uric acid, umol/L 338.22 (335.38, 341.06) 298.52 (296.19, 300.85) <0.001
Fasting glucose, mmol/L 6.51 (6.44, 6.58) 5.82 (5.77, 5.86) <0.001
2-h postload glucose, mmol/L 9.23 (9.06, 9.4) 7.82 (7.7, 7.93) <0.001
HbA1c 6.33 (6.27, 6.38) 5.92 (5.88, 5.95) <0.001
Smoking state, % <0.001
never 43.6 (42.4, 44.9) 56.4 (55.1, 57.6)
former 51.9 (48.2, 55.6) 48.1 (44.4, 51.8)
current 52.1 (49.5, 54.6) 47.9 (45.4, 50.5)
Drinking state, % 0.105
never 44.9 (43.6, 46.3) 55.1 (53.7, 56.4)
former 46.5 (42.0, 50.9) 53.5 (49.1, 58.0)
current 47.4 (45.5, 49.3) 52.6 (50.7, 54.5)
aMean values (95 % confidence interval) or percentages (95 % confidence interval) are shown. SBP systolic blood preesure, DBP dystolic blood preesure, BMI body
mass index
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Associations between clinical types of dyslipidemia and
lipid-related diseases
The prevalence of dyslipidemia type among the over-
all population was depicted in the Additional file 1:
Table S3. In our results, mixed dyslipidemia (13.8 %)
was the most common pattern, isolated hypercholesterol-
emia (Type 1,11.0 %) and isolated hypertriglyceridemia
(Type 2, 10.6 %) came second. Prevalence of low HDL-C
level (Type 3, 5.9 %) was the lowest (Additional file 1:
Table S3). Among subjects with mixed dyslipidemia,
57.9 % (N = 681) were presence of high TC/LDL-C
combined with high TG (Type 4); 41.8 % (N = 491) were
the combination of high TG with low HDL-C level
(Type 5) (Data are not shown).
We then estimated the risks for development of AS,
DM, NAFLD and hyperuricemia. Figure 3 showed the
ORs and 95 % CI for the above five dyslipidemia types
when adjusted potential confounding factors. Patients
with type 4 had the highest risk for development of AS,
nearly 1.5 times over that of non-dyslipidemia (Fig. 3a,
OR = 1.47, P < 0.001). For type 1 and type 2, the risks of
AS were increased by 1.4 and 1.3 fold, respectively
(Fig. 3a, OR = 1.37, P < 0.001; OR = 1.27, P < 0.001).
Analogously, in comparison with other phenotypes, pa-
tients with type 4 were also most likely to suffer from
diabetes, and risk had almost increased 200 % than
non-dyslipidemia (Fig. 3b, OR = 1.92, P < 0.001); type 2
came subsequently.
When taking NAFLD into our logistics analysis, pa-
tients with type 5 had the greatest risk of NAFLD than
other types, a 3.3-fold increase in risk was found (Fig. 3c,
OR = 3.30, P < 0.001). Type 1 was not significant for
NAFLD (Fig. 3c, P = 0.396). We conducted similar ana-
lysis for the development of hyperuricemia, the ORs of
above types were all significant, with type 5 highest
(Fig. 3d, OR = 1.99, P < 0.001).
As was shown in Additional file 1: Table S3, we further
evaluated the concentration-effect relationships between
the significantly single lipid parameter and the objective
indexes for AS, DM, NAFLD and hyperuricemia. For ex-
ample, TC/LDL-C had a positive association with CIMT,
and in other words, the CIMT thickness were elevated
by 0.038/0.048 respectively as every increase in the SD of
the TC and LDL-C levels. By such analogy, positive corre-
lations were observed between the level of TC/LDL-C/TG
and fasting glucose. Additionally, TG had positive relation
with ALT or AST, for HDL, the correlation was reverse
with ALT only. And, positive correlations were found
between TC, LDL-C, TG and serum uric acids, reversely
for HDL-C (Additional file 1: Table S4).
Discussion
In this study, nearly half (45.8 %) participants aged
18 years suffered dyslipidemia from rural areas in
Shandong Province, with low awareness, treatment and
control. Logistic regression indicated that the presence
of high cholesterol was mainly associated with AS.
And triglyceride abnormality was closely associated
with the development of NAFLD and DM.
Our results suggested that the prevalence of dyslipid-
emia had increased by 2.5 folds than that in 2002 (18.6 %)
among the Chinese population [5]. Furthermore, the lipid
profiles have changed greatly. Combined previous rural
study [20], the prevalence of high TC had raised by 7-8
folds than the proportion reported in 2002 [5]. Compared
to the results of some urban areas such as Beijing and
Shenzhen, the values of HDL-C and TG were also
gradually approaching the urban levels, for f TC, the
level was almost higher [21]. Prevalence of western
diets (high intake of fat and cholesterol) in current China
contributes largely to such phenomenon [22]. These
striking findings alarmed the rapid epidemic trend of
dyslipidemia in rural China, which have emerged as
importantly modifiable risk factors in predicting CVD
morbidity and mortality, together with obesity and
smoking [23].
A meta-analysis study previously reported that awareness,
treatment, and control rates of dyslipidemia in China were
24.4 % (95 % CI: 14.4–38.4 %), 8.8 % (95 % CI: 7.7–10.0 %),
Table 2 Gender-specific proportion (95 % Confidence Interval)
of ATP III classification of total, LDL, and HDL cholesterol and




<5.18 47.0 (45.9, 48.1) 46.3 (44.6, 48.0) 47.5 (46.1, 48.9)
5.18–6.21 34.4 (33.4, 35.4) 35.6 (34.0, 37.2) 33.6 (32.3, 34.9)
≥6.22 18.6 (17.8, 19.4) 18.2 (16.9, 19.5) 18.9 (17.8, 20.0)
LDL cholesterol, mmol/L
<2.59 29.1 (28.1, 30.1) 26.5 (25.0, 28.0) 30.9 (29.6, 32.2)
2.59–3.36 38.0 (37.0, 39.0) 39.0 (37.4, 40.6) 37.4 (36.1, 38.7)
3.37–4.13 23.0 (22.1, 23.9) 25.2 (23.7, 26.7) 21.6 (20.5, 22.7)
4.14–4.91 7.4 (6.8, 8.0) 7.1 (6.2, 8.0) 7.6 (6.9, 8.3)
≥4.92 2.4 (2.1, 2.7) 2.2 (1.7, 2.7) 2.5 (2.1, 2.9)
HDL cholesterol, mmol/L
<1.04 12.7 (12.0, 13.4) 19.5 (18.2, 20.8) 8.3 (7.5, 9.1)
1.04–1.54 59.3 (58.3, 60.3) 58.7 (57.0, 60.4) 59.8 (58.5, 61.1)
≥1.55 27.9 (26.9, 28.9) 21.9 (20.5, 23.3) 32.0 (30.7, 33.3)
Triglycerides, mmol/L
<1.70 75.7 (74.8, 76.6) 71.4 (69.9, 72.9) 78.5 (77.4, 79.6)
1.70–2.25 11.6 (10.9, 12.3) 12.0 (10.9, 13.1) 11.4 (10.5, 12.3)
2.26–5.63 11.2 (10.5, 11.9) 13.8 (12.6, 15.0) 9.5 (8.7, 10.3)
≥5.64 1.5 (1.2, 1.8) 2.8 (2.2, 3.4) 0.6 (0.4, 0.8)
LDL low density lipoprotein, HDL high density lipoprotein
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Fig. 1 Trends in age-specific proportion (95 % Confidence Interval) of ATP III classification of total (a), LDL (b), and HDL (c) cholesterol and triglyc-
erides (d) in the overall participants. Linear trends were tested using linear-by-linear association
Fig. 2 Awareness, treatment and control of dyslipidemia. a The total and gender-specific awareness, treatment and control of dyslipidemia. b The
age-specific awareness of dyslipidemia. c The age-specific treatment of dyslipidemia. d The age-specific control rate of dyslipidemia.*P <0.05
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and 4.3 % (95 % CI: 4.1–4.5 %) [24], which were in ac-
cordance with our results. The high prevalence and
poor control called for urgent attention on dyslipidemia
than ever before in China, which undoubtedly will depress
the subsequent morbidity and mortality, raise economic
benefit and save hygienic resources for the whole society
in the long run. It is worth mentioning that some devel-
oped countries had noticed the fact and achieved desirable
succeeds. For example, in recent years, favorable trends in
lipid levels have occurred in Americans, with the aware-
ness of dyslipidemia on CVD risks [25]. The mean levels
of TC declined from 5.44 to 5.18 mmol/L; between 1976
to 1980 and 1999 to 2006. Additionally, the mean concen-
trations of LDL-C declined from 3.37 to 3.08 mmol/L
during 1976–1980 and 1999–2006.
Although the mechanisms between abnormal lipids and
lipid-related diseases had been partly tested, there are con-
flicting data about the role of single lipid changes and
certain lipid combination on other concurrent diseases.
Notably, the prevalence of dyslipidemia now has increased
greatly and lipid profiles have changed apparently. In that
way, were the above changes associated with other non-
communicable diseases? Therefore, we further explored
the odd ratios between the above lipid phenotypes and
AS, DM, NAFLD and hyperuricemia, which is beneficial
for health-workers to establish the orientation and em-
phasis of prevention and treatment in the future.
Our results showed that the risks of dyslipidemia have
altered obviously. The findings in the Multi-Ethnic Study
of Atherosclerosis (MESA) previously also found combined
hyperlipidemia and simple hypercholesterolemia were as-
sociated with increased CIMT [26], which was congruent
with our logistic regression results. In these lipid com-
binations, high cholesterol was general, illustrating the
important effect on the development on AS. Combined
with the high prevalence of abnormal high TC, these
findings further provided strong evidence for the higher
incidence of CVD risks; moreover they strengthened the
rationale for the priority of circulating cholesterol concen-
trations over both HDL-C and TG levels as the primary
target for lipid therapy in ATP III program [12].
For patients with dyslipidemia, the risk for NAFLD was
highest with a 3.3-fold over that of non-dyslipidemia;
followed by hyperuricemia and diabetes, with 2-fold
increase. These results may be an explanation for the
striking increase of prevalence of NAFLD and DM
[27–29]. In this study, the common dyslipidemia type
for patients with NAFLD and DM was type 4, type 5
and type 2, and the core lipid component was the presence
of high TG. These findings implied the great risk of TG in
the development of DM and NAFLD, which had common
lipid-induced pathogenesis-lipotoxicity. Previous studies
had shown that diabetes and NAFLD were both charac-
terized by elevated triglycerides, low HDL-cholesterol
and the predominance of small dense LDL particles
[29–32]. The accumulation of TGs in liver and pancreas
undoubtedly result in the disturbance of lipids balance
and overproductions of free fatty acids, which would trig-
ger the insulin resistance and mitochondrial dysfunction
attributable for the damage of liver and islet normal
Fig. 3 Adjusted odds ratios for the development of atherosclerosis (a), diabetes mellitus (b), NAFLD (c) and hyperuricemia (d) when associated
with different lipid combinations, compared with the subgroup without dyslipidemia. Type 1, isolated hypercholesterolemia; Type 2, isolated
hypertriglyceridemia; Type 3, low HDL-C level alone; Type 4, high TC/LDL-C + high TG;Type 5, high TG + low HDL-C
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function [31, 33]. Compared with high cholesterol, the
abnormality of TG was more closely associated with diet
and lifestyle changes, more easy and feasible to modify,
therefore it is easier to achieve control and benefit quickly
for patients, which also may reduce the risk of NAFLD
and DM in the long run.
Certain potential limitations may exist in our study.
First, women were overrepresented due to large number
of male migrant workers ineligible for this investigation,
and the results may be not suitable for other ethnicity.
Secondly, this was a cross-sectional study, and therefore
any causality cannot be proved.
Conclusion
In summary, dyslipidemia has become a serious public
health problem in rural population of North China. There
is lack of awareness, treatment and effective control among
the population. The rapid increase of high TC and higher
risk of high TG may give rise to the high epidemic of
AS, NAFLD and DM. It is urgent and imperative to ap-
propriately develop individualized prevention and treat-
ment guidelines within one person according to the
dyslipidemia type, which undoubtedly depress the subse-
quent morbidity and mortality, raise economic benefit and
save hygienic resources for the whole society.
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